Mode of action
- GLP-1 receptors: less appetite
- GIP receptors: appetite and blood sugar control
- Glucagon receptors: may raise energy use (being studied)

Investigational triple agonist (GLP-1, GIP and glucagon) studied for obesity. Not an approved medicine.

Being studied for obesity and long-term weight management, and for related metabolic benefits.
Not an approved dose. A vial's total peptide amount is not the same as its concentration per mL.
Once a week under the skin, in trials only. Not an approved medicine or dosing advice. It cannot replace an approved drug; use only in authorized research.
| Receptor | What it does | |
|---|---|---|
| GLP-1 | Lowers appetite, slows stomach emptying, helps insulin release | Yes |
| GIP | Helps insulin release and appetite and energy control | Yes |
| Glucagon | Being studied for raising energy use | Yes |
Source: Lilly TRIUMPH-1 release, May 21, 2026: 2,339 adults without diabetes. Investigational drug. Average % of body weight lost at 80 weeks.
Source: Jastreboff et al., NEJM (retatrutide for obesity); Lilly TRIUMPH-1 release, May 21, 2026. The label on every PeptoPlus unit hides a one-time code under a scratch layer, with a QR beside it. Scan it to check that the code was issued by PeptoPlus.